bioAffinity prices $4M private placement to fund cancer diagnostics push

bioAffinity Technologies has secured $4 million through a private placement priced at market value to support its development of noninvasive cancer diagnostics, indicating a focused capital raise to extend operational runway rather than scale rapidly.

This Wire brief sits within Fusion42's coverage of Biotech.